Background: () is highly expressed in several hematopoietic malignancies. However, the role of in the carcinogenesis and progression of colorectal cancer (CRC) patients has rarely been reported.
Methods: In this study, the data were collected from The Cancer Genome Atlas and Gene Expression Omnibus databases. The diagnostic value of was analyzed by the R package "pROC." The overall survival was estimated using the "survival" and "survminer" packages. A nomogram was established to predict 1-, 3-, and 5-year overall survival of CRC patients. The CIBERSORT software was employed to calculate the relative proportions of 22 immune cells.
Results: expression was downregulated in CRC patients. Remarkably, expression was increased with stage (stage I-stage III) of CRC, and the CRC patients with high expression exhibited a poor prognosis. The promoter methylation level of was prominently increased in CRC samples compared to paracancerous samples. We also found that the six miRNAs target genes, leading to its downregulation, and expression had a negative correlation with its downstream target gene in both CRC and normal samples. Finally, we found that the 12 immune infiltrating cells were observably different between high and low expression groups. The had a significant positive correlation with 8 immune checkpoints (PD-1 (PDCD1), CTLA4, PDL-1 (CD274), PDL-2 (PDCD1LG2), CD80, CD86, LAG3, and TIGIT) expressions.
Conclusion: probably played a carcinostasis role in the early stages of CRC but exhibited a cancer-promoting effect in the advanced stages. Meanwhile, could serve as a reliable prognostic indicator for CRC.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505080 | PMC |
http://dx.doi.org/10.1155/2023/5521544 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!